Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gen-orph s.a.s. - bosentan monohydrate 129,082 mg - eq. bosentan 125 mg - film-coated tablet - 125 mg - bosentan monohydrate 129.082 mg - bosentan

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - bosentan monohydrate 129,082 mg - eq. bosentan 125 mg - film-coated tablet - 125 mg - bosentan monohydrate 129.082 mg - bosentan

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - bosentan monohydrate 64,541 mg - eq. bosentan 62,5 mg - film-coated tablet - 62,5 mg - bosentan monohydrate 64.541 mg - bosentan

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - bosentan monohydrate 64,541 mg - eq. bosentan 62,5 mg - film-coated tablet - 62,5 mg - bosentan monohydrate 64.541 mg - bosentan

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - bosentan monohydrate 129,082 mg - eq. bosentan 125 mg - film-coated tablet - 125 mg - bosentan monohydrate 129.082 mg - bosentan

Bandaríkin - enska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - bosentan (unii: q326023r30) (bosentan anhydrous - unii:xul93r30k2) - bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1): ·         in adults  to improve exercise ability and to decrease clinical worsening. studies establishing effectiveness included predominantly patients with who functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (60%), pah associated with connective tissue diseases (21%), and pah associated with congenital heart disease with left-to-right shunts (18%) [see clinical studies (14.1)] . use of bosentan tablets are contraindicated in females who are or may become pregnant. to prevent pregnancy, females of reproductive potential must use two reliable forms of contraception during treatment and for one month after stopping bosentan tablets [see boxed warning, warnings and precautions (5.2), drug interactions (7.2), use in specific populations (8.1)] . co-administration of cyclosporine a and bosentan resulted in markedly increased plasma concentrations of bosentan. therefore, concomitant

Bandaríkin - enska - NLM (National Library of Medicine)

alembic pharmaceuticals limited - bosentan (unii: q326023r30) (bosentan anhydrous - unii:xul93r30k2) - bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1): ·         in adults  to improve exercise ability and to decrease clinical worsening. studies establishing effectiveness included predominantly patients with who functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (60%), pah associated with connective tissue diseases (21%), and pah associated with congenital heart disease with left-to-right shunts (18%) [see clinical studies (14.1)] . use of bosentan tablets are contraindicated in females who are or may become pregnant. to prevent pregnancy, females of reproductive potential must use two reliable forms of contraception during treatment and for one month after stopping bosentan tablets [see boxed warning, warnings and precautions (5.2), drug interactions (7.2), use in specific populations (8.1)] . co-administration of cyclosporine a and bosentan resulted in markedly increased plasma concentrations of bosentan. therefore, concomitant

Ísrael - enska - Ministry of Health

taro international ltd, israel - bosentan as monohydrate - film coated tablets - bosentan as monohydrate 125 mg - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv. reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

Ísrael - enska - Ministry of Health

taro international ltd, israel - bosentan as monohydrate - film coated tablets - bosentan as monohydrate 62.5 mg - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv. reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

Kanada - enska - Health Canada

pharmascience inc - bosentan (bosentan monohydrate) - tablet - 62.5mg - bosentan (bosentan monohydrate) 62.5mg - vasodilating agents